← Leaderboards
Sean X Leng
Johns Hopkins University
$11,597,269
Attributed
$14,184,386
Total exposure
8
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,184,386 · 8
By mechanism
U01$6,605,926 · 1
R01$2,814,095 · 1
U54$1,588,869 · 1
R21$1,260,010 · 3
R42$1,051,486 · 1
K23$864,000 · 1
Top collaborators
- Joshua M Hare3 shared
- Anthony Andrew Oliva3 shared
- Jay H. Bream2 shared
- Joseph B. Margolick2 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Todd T Brown$33,742,320
- Linda P Fried$18,538,317
- Andrea L Cox$41,369,991
- Guang William Wong$7,353,539
- Peter M. Abadir$6,408,859
Others in their field
Top investigators on “Frailty”
- Adrian Hernandez · Duke University$50,769,596
- Linda J Waite · University Of Chicago$46,791,622
- Josef Coresh · New York University School Of Medicine$42,941,379
- Rose A Gubitosi-Klug · Case Western Reserve University$35,307,043
- Dalane W Kitzman · Wake Forest University$35,057,793
- Amy Caroline Justice · Philadelphia Va Medical Center$22,662,211
Research focus
FrailtyElderlyImmuneT-LymphocyteAgingInfluenza VaccinationInfluenzaVaccinesImmunityCommunitiesVaccinationProgramsResponseAmericanCytokineInfectionInsightInvestigationCellsImmunosenescencePeripheral Blood Mononuclear CellFrail ElderlyAffectImmune System
Grant awards (28)
Leveraging an ongoing longitudinal study of influenza vaccination to define immune signatures of response and risk of infection in older adults >75$1,583,019
U01 · FY2025 · AI · contact PI
Leveraging an ongoing longitudinal study of influenza vaccination to define immune signatures of response and risk of infection in older adults >75$1,700,968
U01 · FY2024 · AI · contact PI
Leveraging an ongoing longitudinal study of influenza vaccination to define immune signatures of response and risk of infection in older adults >75$1,688,993
U01 · FY2023 · AI · contact PI
Leveraging an ongoing longitudinal study of influenza vaccination to define immune signatures of response and risk of infection in older adults >75$1,632,946
U01 · FY2022 · AI · contact PI
Sex differences in the impact of frailty on vaccine-induced immune responses in community-dwelling older adults$374,483
U54 · FY2022 · AG · contact PI
Sex differences in the impact of frailty on vaccine-induced immune responses in community-dwelling older adults$328,230
U54 · FY2021 · AG · contact PI
A Randomized, Blinded, Placebo-Controlled Clinical Trial to Evaluate Longeveron Mesenchymal Stem Cell (LMSC) Therapy for Treating The Metabolic Syndrome$435,997
R42 · FY2020 · AG
Sex differences in the impact of frailty on vaccine-induced immune responses in community-dwelling older adults$328,228
U54 · FY2020 · AG · contact PI
T-cell responses to CMV as a determinant of systemic immune activation$204,688
R21 · FY2020 · AG
A Randomized, Blinded, Placebo-Controlled Clinical Trial to Evaluate Longeveron Mesenchymal Stem Cell (LMSC) Therapy for Treating The Metabolic Syndrome$465,489
R42 · FY2019 · AG
Sex differences in the impact of frailty on vaccine-induced immune responses in community-dwelling older adults$328,229
U54 · FY2019 · AG · contact PI
T-cell responses to CMV as a determinant of systemic immune activation$245,625
R21 · FY2019 · AG
Influenza vaccine failure in adults over age 75: role of chronic CMV infection$625,443
R01 · FY2018 · AI · contact PI
Sex differences in the impact of frailty on vaccine-induced immune responses in community-dwelling older adults$229,699
U54 · FY2018 · AG · contact PI
Influenza vaccine failure in adults over age 75: role of chronic CMV infection$624,028
R01 · FY2017 · AI · contact PI
A Randomized, Blinded, Placebo-Controlled Clinical Trial to Evaluate Longeveron Mesenchymal Stem Cell (LMSC) Therapy for Treating The Metabolic Syndrome$150,000
R42 · FY2017 · AG
Influenza vaccine failure in adults over age 75: role of chronic CMV infection$601,128
R01 · FY2016 · AI · contact PI
Influenza vaccine failure in adults over age 75: role of chronic CMV infection$477,872
R01 · FY2015 · AI · contact PI
Influenza vaccine failure in adults over age 75: role of chronic CMV infection$485,624
R01 · FY2014 · AI · contact PI
Chronic CMV infection in the elderly: diagnosis and link to chronic inflammation$202,500
R21 · FY2014 · AG · contact PI
Chronic CMV infection in the elderly: diagnosis and link to chronic inflammation$243,000
R21 · FY2013 · AG · contact PI
Vaccine-Induced Immunity against Influenza in Frailty$159,195
K23 · FY2010 · AG · contact PI
Vaccine-Induced Immunity against Influenza in Frailty$162,821
K23 · FY2009 · AG · contact PI
Vaccine-Induced Immunity against Influenza in Frailty$202,178
K23 · FY2008 · AG · contact PI
Vaccine-Induced Immunity against Influenza in Frailty$199,174
K23 · FY2007 · AG · contact PI
Vaccine-Induced Immunity against Influenza in Frailty$140,632
K23 · FY2006 · AG · contact PI
Inflamation-Gene Expression by Monocytes in Frailty$198,653
R21 · FY2005 · AG
Inflammation-Gene Expression by Monocytes in Frailty$165,544
R21 · FY2004 · AG